Latest news

• Bayer and Regeneron to develop second wet AMD therapy

  The partners already market Eylea (aflibercept) for use in a number of eye disorders, including wet AMD, and now want to develop a complementary therapy that can be used in combination ... The companies are banking on the two drugs complementing each

• NICE backs two eye treatments

  The National Institute for Heath and Care Excellence (NICE) today recommended two treatments for eye disorders for use on the NHS in England and Wales. ... Pathological myopia is a chronic form of myopia, which is characterised by excessive lengthening

• ReNeuron wins orphan status for stem cell therapy

  ReN003 is being assessed as a treatment for rare eye disorder retinitis pigmentosa. ... of inherited eye disorders that affect the retina and can cause severe impairment to vision.

• Lucentis cleared in Europe for pathological myopia

  Pathological myopia affects 1 to 3 per cent of the world's population, in some patients leads to the growth of abnormal leaky blood vessels in the back of the eye ... in visual acuity after just two injections into the affected eye.

• FDA approves Alcon eye drug Simbrinza

  Fixed-combination licensed to treat glaucoma patients in the US. Novartis subsidiary Alcon has been given a boost after US regulators approved its fixed-combination eye treatment Simbrinza Suspension. ... This pressure is the only modifiable risk factor